Stomach

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Retrieved on: 
Friday, April 26, 2024

The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation.

Key Points: 
  • The European Commission (EC), which has the authority to approve medicines for the European Union (EU), will now review the CHMP recommendation.
  • “New treatment options that may improve responses, delay disease progression, and offer survival benefit in the first-line setting are needed.
  • On March 7, 2024 the U.S. Food and Drug Administration (FDA) approved the use of Opdivo in combination with cisplatin and gemcitabine as a first-line treatment for adult patients with unresectable or metastatic urothelial carcinoma, following a Priority Review.
  • Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -901 clinical trial.

HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting

Retrieved on: 
Wednesday, April 24, 2024

HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting May 31-June 4, 2024, in Chicago, IL.

Key Points: 
  • HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted with one poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting May 31-June 4, 2024, in Chicago, IL.
  • “The ASCO meeting is an important opportunity to share our unique lipid-based technology with other clinical investigators,” said Yuhong Xu, Ph.D., Founder and CEO of HighField.
  • HFK1 is a drug encapsulated immunoliposome containing doxorubicin for patients with advanced refractory solid tumors having HER2 low and HER2+ expression.
  • HF1K16 is a drug encapsulated immune modulating liposome containing all-trans retinoic acid (ATRA) for patients with recurrent and refractory glioma.

Bayer Introduces Iberogast™ in the U.S., Bringing Proven Plant-Based Relief to the Millions Who Experience Gut Health Issues

Retrieved on: 
Wednesday, April 24, 2024

Iberogast helps reduce stomach acid, regulate stomach muscles, calm gut nerves, and support both the gut lining and microbiome.

Key Points: 
  • Iberogast helps reduce stomach acid, regulate stomach muscles, calm gut nerves, and support both the gut lining and microbiome.
  • *
    Caraway helps relax certain intestinal muscles, reduces acidity in the stomach and helps relieve occasional indigestion when combined with peppermint.
  • “With tens of millions of Americans experiencing occasional digestive health issues, this clinically proven, game-changing product will allow them to experience the power of nature and its incredible abilities to support gut health.
  • Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition.

AI Medical Service Inc. Completes First Pharmaceutical Registration of Gastric AI-based Endoscopic Diagnosis Support System from Brazil’s ANVISA

Retrieved on: 
Monday, April 22, 2024

AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the first instance of Brazilian pharmaceutical registration of an AI-based endoscopic diagnostic support device that operates within the stomach (product name: gastroAI, model name: model G).

Key Points: 
  • AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, is excited to announce the first instance of Brazilian pharmaceutical registration of an AI-based endoscopic diagnostic support device that operates within the stomach (product name: gastroAI, model name: model G).
  • The endoscopic AI assists the physician in diagnosis of neoplasia during endoscopy by detecting lesion candidates for biopsy(*1) or other additional diagnostic steps based on gross visual features.
  • AIM has confirmed that this is the first case of pharmaceutical registration in Brazil for an endoscopic support software that operates within the upper gastrointestinal tract(*2).
  • Nevertheless, early-stage gastric cancer is difficult to detect and is said to be missed in 4.5 to 25.8% of cases.

AI Medical Service Inc. Signs Joint Research Agreement with Mahidol University in Thailand

Retrieved on: 
Monday, April 22, 2024

AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, signed a joint research agreement with Mahidol University in Thailand (hereinafter Mahidol) on March 1, 2024, and began research activities on April 1, 2024.

Key Points: 
  • AI MEDICAL SERVICE INC. (hereinafter AIM), a medical start-up specializing in the development of diagnostic endoscopic AI, signed a joint research agreement with Mahidol University in Thailand (hereinafter Mahidol) on March 1, 2024, and began research activities on April 1, 2024.
  • AIM is the first Japanese company to sign a joint research agreement with Mahidol in the field of endoscopic AI, and Mahidol is the first Thai institute that AIM has collaborated with thus far1.
  • View the full release here: https://www.businesswire.com/news/home/20240418278652/en/
    AIM has initiated joint research with Mahidol to assess the practicality of its endoscopic AI.
  • Collaboration with Mahidol will facilitate joint research designed to test the applicability of Japanese endoscopic AI in Thailand.

Isobar Science: Defining Contamination Sources using Boron Isotopes

Retrieved on: 
Thursday, April 25, 2024

MIAMI, April 25, 2024 /PRNewswire/ -- Isobar Science performs high-quality boron isotope analysis in water samples for contaminant source tracking.

Key Points: 
  • MIAMI, April 25, 2024 /PRNewswire/ -- Isobar Science performs high-quality boron isotope analysis in water samples for contaminant source tracking.
  • Isobar Science uses high-quality boron isotope analysis in water for contaminant source tracking.
  • Nonpoint source pollution comes from ill-defined sources, are difficult to regulate and usually vary spatially and temporally (e.g.
  • Boron (δ11B) isotopes can provide insights into the location and source of excess nutrients entering the environment.

ImmPACT Bio to Present New Ex Vivo Preclinical Data for Bispecific Claudin 18.2/TGF-β CAR T Program at the American Society of Gene & Cell Therapy 27th Annual Meeting

Retrieved on: 
Monday, April 22, 2024

LOS ANGELES, April 22, 2024 /PRNewswire/ -- ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new generation of cellular therapies that have the potential to bring transformational benefits to patients, today announced that it will present new ex vivo preclinical data for ImmPACT Bio's bispecific Claudin 18.2 (CLDN18.2)/TGF-β chimeric antigen receptor (CAR) T program for the treatment of solid tumors that express CLDN18.2, including gastric and gastroesophageal junction cancer, as part of a poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, taking place in Baltimore, MD from May 7-11, 2024 and virtually.

Key Points: 
  • "There is a significant unmet medical need in patients with gastric cancer, which is among the top three deadliest cancers globally.
  • CLDN18.2 has emerged as a promising target due to its elevated expression in tumor cells but not healthy cells.
  • Previous CAR T-cell therapies targeting CLDN18.2 have demonstrated promise but lacked durability, likely due to poor T-cell persistence and function in solid tumors," said Sumant Ramachandra, M.D., Ph.D., chief executive officer of ImmPACT Bio.
  • "We are using a novel bispecific approach designed to enhance CAR T-cell activity in solid tumors by overcoming immune suppression in the tumor microenvironment.

NUH LAUNCHES NEW DIGESTIVE CENTRE TO PUSH NEW FRONTIERS IN EARLY CANCER DETECTION AND CARE EXCELLENCE

Retrieved on: 
Tuesday, April 16, 2024

SINGAPORE, April 16, 2024 /PRNewswire/ -- The National University Hospital (NUH) is embarking on a major initiative to establish the National University Centre for Digestive Health, slated for completion in the first half of 2025. With a vision to be the region's leading academic centre for digestive health, the Centre will pioneer research, innovations and clinical practices with an amplified focus to elevate the standards of early disease detection, precise diagnosis, treatment and prevention of digestive illnesses.

Key Points: 
  • Early gastrointestinal lesions, which are abnormal changes involving the tissues in the stomach area, may be indicative of cancer.
  • As such, early detection and diagnosis are crucial for better prognosis and lay a strong foundation for successful treatment and recovery.
  • The team is also developing novel biomarkers to improve the precision of early colorectal cancer detection, as well as new pancreas and liver cancer assays.
  • As we continue to expand our infrastructure and embrace technological advances, the Centre is poised to redefine digestive health for the future."

Sage Veterinary Imaging Opens New Treatment Center in Spring

Retrieved on: 
Thursday, April 11, 2024

SPRING, Texas, April 11, 2024 /PRNewswire/ -- Pets in the Houston area now have access to human-quality imagery to get the treatment they deserve, thanks to the new Sage Veterinary Imaging (SVI). Working closing with local veterinarians, SVI offers the latest research-grade technology to obtain highly detailed images that enable accurate diagnosis and effective treatment plans for area pets. The new clinic is located at 8101 Cypresswood, Spring.

Key Points: 
  • SPRING, Texas, April 11, 2024 /PRNewswire/ -- Pets in the Houston area now have access to human-quality imagery to get the treatment they deserve, thanks to the new Sage Veterinary Imaging (SVI).
  • "Our mission is to help find answers fast using our human-quality imaging, and work with local veterinarians to deliver the treatment your pet needs."
  • Sage Veterinary Imaging is accredited by the American College of Veterinary Radiology (ACVR) as a teaching hospital, and the Spring clinic includes:
    3T magnetic resonance imaging (MRI).
  • The Spring imaging center is the third location for SVI; other imaging centers are located in Sandy, Utah, and Round Rock, Texas.

Gender-nonconforming ancient Romans found refuge in community dedicated to goddess Cybele

Retrieved on: 
Thursday, April 25, 2024

Approved by the pope on March 25, 2024, the Vatican declaration asserts the Vatican’s opposition to gender-affirming surgery and surrogacy.

Key Points: 
  • Approved by the pope on March 25, 2024, the Vatican declaration asserts the Vatican’s opposition to gender-affirming surgery and surrogacy.
  • Even in the ancient Roman Empire, individuals could transgress traditional conceptions of gender roles in various ways.
  • As a scholar of Greek and Latin literature, I have studied the “Galli,” male followers of the goddess Cybele.

Cybele: Mother of the gods


In the philosophical treatise “Hymn to the Mother of the Gods,” Julian the Philosopher, the last pagan emperor of the Roman empire, writes about the history of the cult of Cybele. In this treatise, he describes the cult’s main figures and how some of its rites were performed.

  • Often referred to as the Mother of the Gods, Cybele was first worshiped in Anatolia.
  • Cybele’s cult gave rise to a group of male followers, or attendants, known as Galli.
  • Among the surviving material evidence related to their existence are sculptures, as well as a Roman burial of an individual Gallus discovered in Northern England.

Attis: Cybele’s human companion


A statue from Ostia, Rome’s port city, depicts a reclining Attis, Cybele’s youthful male human companion.

  • In their tellings of Cybele’s myth, Greek and Roman authors give differing versions for Attis’ self-castration.
  • The Roman poet Catullus describes how Cybele puts Attis into a state of frenzy, during which he castrates himself.

Material evidence for the Galli


A relief sculpture from Lanuvium, now at the Musei Capitolini in Rome and dated to the second century C.E, is one of the few surviving representations of a Gallus.

  • The sculpted figure is adorned with an elaborate headdress or crown, a torque necklace and a small breastplate, as well as ornate clothing.
  • At Cataractonium, a Roman fort in Northern England, a skeleton was uncovered in the necropolis of Bainesse during excavations in 1981-82.
  • An examination of the bones, however, revealed that the remains were those of a young man – likely in his early twenties.

Respect for Galli

  • Galli, unlike other men in Rome or its empire, were able to openly present themselves or live as women, regardless of their assigned sex or how they identified.
  • Catullus’ poem and comments by other authors indicate that they perceived the gender of the Galli as differing from Roman concepts of masculinity.
  • However, the Galli were also, reluctantly, respected for the role they played in Cybele’s cult.
  • It is tempting to see the Galli as nonbinary or transgender individuals, even though the Romans did not know or use concepts such as nonbinary or transgender.


Tina Chronopoulos does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.